Core Viewpoint - Hydreight Technologies Inc. has provided revenue guidance for fiscal year 2026, projecting approximately $150 million in revenue, which reflects a conservative baseline outlook based on contracted demand and partner activity [2][6]. Fiscal 2026 Revenue Guidance - The company expects fiscal 2026 revenue of around $150 million, which is a conservative estimate based on existing pharmacy operations and digital health platform activities [2]. - This guidance does not include potential contributions from acquisitions, new market entries, or additional commercial arrangements that are not currently operational [2][6]. Q1 2026 Revenue Outlook - For the first quarter of fiscal 2026, the company anticipates revenue between $25 million and $28 million, driven by major partnerships and pharmacy product lines that are set to go live [3]. Cost Structure, Margin, and Profitability Context - The fiscal 2026 guidance assumes no significant increase in fixed operating costs compared to late 2025 levels, with revenue growth supported by the existing cost base [4]. - The company expects an Adjusted EBITDA margin of approximately 15-17%, benefiting from scaling transaction volumes across a largely fixed operating cost structure [5]. Management Commentary - The CEO of Hydreight emphasized that the guidance reflects the visibility into operations and is grounded in existing demand, supported by a disciplined cost structure [7]. Capital Position - The company recently completed a $15 million financing deal to enhance working capital, which is expected to support anticipated transaction volumes and ongoing operations [9].

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) ("Hydreight" or the "Company"), a leader in U.S. nationwide digital healthcare solutions, is pleased to announce that, further to the news release of the Company dated January 15, 2026, it has closed its previously announced "bought deal" private placement with Canaccord Genuity Corp. ( ...

Core Viewpoint - Hydreight Technologies Inc. has launched a bought deal private placement to raise C$10,003,500 through the issuance of 2,470,000 units at C$4.05 per unit, aimed at accelerating growth and expanding its digital healthcare solutions across the U.S. [1][2] Group 1: Offering Details - The offering consists of 2,470,000 units, each comprising one common share and one half of a common share purchase warrant, with warrants exercisable at C$5.27 within 24 months post-closing [2][3] - An additional option allows underwriters to purchase up to 50% more units at the issue price, potentially raising an additional C$5,001,750 [3] - The offering is expected to close around January 27, 2026, pending necessary regulatory approvals [8] Group 2: Use of Proceeds - Net proceeds from the offering will be allocated to support sales growth, expand pharmacy production lines, and for general corporate purposes [4] Group 3: Company Overview - Hydreight Technologies Inc. operates a mobile clinic network across the U.S., integrating over 2,500 nurses and 100 doctors, with a proprietary platform that facilitates healthcare delivery directly to patients [11] - The platform includes tools for accounting, documentation, sales, inventory, and patient data management, enhancing service delivery by licensed healthcare professionals [11]

Core Insights - Hydreight Technologies Inc. has entered the at-home STI pre-screening market through an exclusive distribution agreement with Health Screen Collective, aiming to address a significant public health challenge in the U.S. [1][3] Company Overview - Hydreight is a digital health platform that provides on-demand care, pharmacy fulfillment, and enterprise healthcare services across the U.S. [1] - The company has established a network of over 3,000 nurses and 300 doctors, along with a pharmacy network, enabling healthcare professionals to deliver services directly to patients [14]. Market Opportunity - Approximately one in five people in the U.S. is living with an STI, with millions of new infections occurring annually, highlighting the need for accessible screening solutions [3][4]. - The at-home STI pre-screening market is expected to grow rapidly, driven by public health guidelines and patient behavior [11]. Product Details - Hydreight will exclusively distribute HSC's at-home STI pre-screen testing kits, which have already secured around 50,000 pre-orders, with deliveries starting in early 2026 [2][12]. - The testing kits provide results in minutes using validated lateral-flow immunoassay technology, allowing for private sample collection at home [5][7]. Clinical Integration - The kits are designed to facilitate a seamless transition from pre-screening to licensed medical review, confirmatory testing, clinical consultation, and treatment coordination [8][9]. - This integrated workflow enhances access and continuity of care, transforming at-home testing into a connected digital healthcare experience [9]. Strategic Importance - The high-frequency nature of STI screening aligns with Hydreight's platform-first strategy, which aims to drive repeat engagement and long-term platform utilization [11][13]. - The initial demand for the pre-screening kits reflects interest from enterprise partners and healthcare operators seeking scalable solutions [12].

Core Insights - Hydreight Technologies Inc. has exceeded its operational target for 2025 by surpassing 1.3 million product orders placed ahead of year-end, reflecting strong platform adoption and partner demand [4][10][11] - The company has expanded its ecosystem to approximately 2,500 licenses, significantly exceeding its target of 1,000 for 2025, although many licenses are still in onboarding stages [7][10] - The focus remains on long-term value creation and disciplined execution as the company prepares for increased platform activity in 2026 [9][10][15] Operational Highlights - VSDHOne, the enterprise-focused vertical, began commercial activity in late June 2025 and has been progressively scaled [3] - The company achieved over 1.3 million product orders placed, surpassing its 2025 operational target, driven primarily by an initial base of approximately 400 fully onboarded licenses [4][10] - Hydreight continues to use product orders placed as its primary operational metric, reflecting real-time platform activity and demand [5][23] License and Platform Expansion - The company supports around 2,500 licenses, with the majority still in onboarding or early activation stages, which are not yet contributing significantly to order volume [7][10] - Management anticipates that utilization will scale progressively as onboarding is completed, positioning the company for increased activity in 2026 [7][15] Average Order Value and Strategic Focus - Average order value (AOV) reflects the early-stage scaling of newer offerings, with a focus on balancing order volume and product mix for long-term value creation [9][10] - The company is committed to building a durable and scalable business, with expectations for platform metrics to evolve as newer verticals mature [10] 2026 Guidance and Future Outlook - Hydreight plans to provide formal 2026 guidance early in the new year, following a review of several strategic initiatives, including enterprise partnerships and M&A opportunities [12][14] - The company is evaluating late-stage opportunities for enterprise customers, which will be incorporated into future guidance for a more accurate business outlook [13][14] Recognition and Growth - Hydreight was ranked as the 56th fastest-growing company in North America on the 2024 Deloitte Technology Fast 500™ and recognized as a top 50 TSX Venture Exchange company [16] - The company is expanding high-volume platform partners and increasing utilization across multiple healthcare categories, while also strengthening compliance and governance [16]

Core Insights - Hydreight Technologies Inc. reported a 132% year-over-year revenue increase in Q3 2025, marking its fourth consecutive quarter of profitability, driven by a diversified multi-vertical business model [3][6][23] Financial Performance - Q3 2025 GAAP revenue reached $10.52 million, a 132% increase compared to Q3 2024 - Topline revenue for Q3 was $12.83 million, up 110% year-over-year - Gross margin for Q3 was $2.33 million, an increase from $1.53 million in Q3 2024 - Adjusted EBITDA for Q3 was $620K, indicating continued operational improvement - GAAP net income for Q3 was $362K, compared to a net loss of $90K in Q3 2024 - For the first nine months of 2025, topline revenue was $26.71 million, up 61% year-over-year, and GAAP revenue was $20.44 million, up 70% year-over-year [6][8][23] Business Model and Growth - Hydreight operates a multi-vertical platform, with GLP-1 treatments accounting for approximately 28% of total platform activity, indicating a balanced and diversified approach [3][4] - The company has seen a 72% year-over-year increase in pharmacy orders, reflecting strong demand and treatment continuity [9] - The nurse network and clinic engagement have shown significant growth, with 198 new nurse sign-ups in Q3 2025, a 49% increase year-over-year [15] VSDHOne Platform - VSDHOne, launched in June 2025, has recorded approximately 295,000 product orders in Q3 and a total of about 887,000 orders since its launch [11][12] - The company aims to reach a target of approximately 1.3 million product orders for 2025, based on existing partner demand [13] Strategic Initiatives - The company is focused on enhancing its operational infrastructure, compliance, and automation processes as part of its 2026 framework [20][22] - Hydreight is expanding into additional treatment categories, including genetics and oral weight management, while also growing its partner ecosystem across the United States [22] Future Outlook - The company plans to release its 2026 guidance in mid-December, with a focus on stability, scale, and continued engagement with shareholders [23]

Core Insights - Victory Square Technologies Inc. reported its financial results for Q3 and nine months ended September 30, 2025, highlighting significant developments across its various platforms, including digital health, biotech, pet wellness, climate tech, and immersive technology [1][4]. Financial Highlights - For Q3 2025, the company achieved adjusted revenue of $12.83 million and GAAP revenue of $10.52 million, with a gross margin of $2.33 million and adjusted EBITDA of $1.26 million [8]. - For the nine months ended September 30, 2025, adjusted revenue reached $26.71 million and GAAP revenue was $20.44 million [8]. Portfolio & Strategic Update - Hydreight Technologies, the flagship digital health subsidiary, continued to drive operational performance, recognized as one of the fastest-growing companies in North America [5][6]. - Hydreight's strategic positioning includes a focus on high-growth health segments such as GLP-1 therapies and hormone optimization, supported by a robust compliance infrastructure [10]. - The company launched a $10 million accelerator to incubate direct-to-consumer health companies scaling on the VSDHOne platform [16]. Digital Health Initiatives - Victory Square supports various digital health platforms, including telehealth and diagnostics, aimed at enhancing metabolic health, dermatology, and preventative health [13]. - The digital health market is experiencing increased adoption, with a projected U.S. healthcare spending reaching $7.2 trillion by 2031 [17]. Biotech and Pet Health Platforms - Insu Therapeutics is advancing its oral insulin tablet development, targeting first-in-human studies for 2026 [19][23]. - Pawsible Ventures launched a $10 million fund to accelerate innovation in pet health, aiming to support 15-20 companies over the next three years [19]. Immersive Technology - XR Immersive Tech is expanding into health-related intellectual property, focusing on digital health applications and patient education [20][24]. - Current development areas include digital twin models for chronic-condition tracking and immersive patient engagement tools [21][27]. Additional Notes - Victory Square manages a diversified portfolio of over 20 companies across various sectors, including digital health, AI, and climate tech [26][35]. - The company is actively reviewing monetization opportunities for non-core assets, including a recent Normal Course Issuer Bid allowing the repurchase of up to 5 million common shares [26].

Core Insights - Hydreight Technologies Inc. has successfully closed a strategic partnership transaction with Perfect Scripts LLC, acquiring a 5% membership interest in exchange for 2,250,000 common shares valued at CAD$2.30 each [1][2] - The partnership aims to establish a 503B pharmacy in the U.S., allowing Hydreight to secure the lowest pricing for products sold by Perfect Scripts and its subsidiaries [2][8] - The U.S. compounding pharmacy sector is projected to grow from $6.31 billion in 2024 to $10.76 billion by 2033, indicating significant market potential for Hydreight's expansion [8] Company Overview - Hydreight operates a fully integrated mobile clinical network comprising over 2,500 nurses and 100 doctors across the U.S., providing healthcare services directly to patients [14] - The company has a 503B pharmacy network servicing all 50 states and is closely affiliated with a certified e-script and telemedicine provider network [14] - Hydreight's proprietary platform includes tools for accounting, documentation, sales, inventory, and patient data management, enhancing service delivery [14] Partnership Details - The transaction includes a Pro-Rata Investment Right allowing Hydreight to maintain its interest in Perfect Scripts and an option to acquire up to 40% of its membership interests [2][3] - Restrictions have been placed on the number of Hydreight shares that can be issued to Perfect Scripts, capping total shares at 12,000,000 [3] - A cash finder's fee of $258,750 was paid, representing 5% of the transaction's deemed value [4] Perfect Scripts Overview - Perfect Scripts LLC is the parent company of PerfectRx LLC and operates a 503A retail pharmacy in Iowa, with a distribution center in Florida [9][10] - PerfectRx is a HIPAA-compliant mail-order pharmacy capable of processing over 150,000 prescriptions daily, with infrastructure to handle demand surges [10][11] - The company utilizes its proprietary PerfectOS platform for digital prescription intake and real-time inventory management [10][11]

Core Insights - Hydreight Technologies Inc. reported significant financial growth in Q3 2025, with a focus on expanding its VSDHOne platform and achieving strategic objectives for 2026 [1][5][10] Financial Performance - For the first nine months of 2025, topline revenue reached CAD 26.71 million, a 61% increase year-over-year, while GAAP revenue was CAD 20.44 million, up 70% [5][7] - Q3 2025 topline revenue was CAD 12.83 million, marking a 110% increase compared to Q3 2024, with GAAP revenue at CAD 10.52 million, a 132% increase [5][7] - Q3 2025 gross margin improved to CAD 2.33 million from CAD 1.53 million in Q3 2024, and adjusted EBITDA was CAD 620K, indicating continued operational improvement [5][7] - The company reported a GAAP net income of CAD 362K in Q3 2025, a significant turnaround from a net loss of CAD 90K in Q3 2024 [5][7] Business Development - Hydreight processed approximately 295,000 VSDHOne product orders between July and September 2025, reflecting broad growth across various wellness verticals [5][10] - The nurse network expanded with 198 new sign-ups in Q3 2025, a 49% increase year-over-year, totaling 593 sign-ups in the first nine months of 2025, up 63% from 2024 [5][10] - Pharmacy orders increased by approximately 72% year-over-year, indicating sustained growth and broader adoption of services [5][10] Strategic Initiatives - The company signed a definitive agreement to acquire a 5% equity stake in Perfect Scripts, LLC, with an option to increase to 40%, establishing a strategic partnership [5][10] - Hydreight is actively evaluating profitable multi-state wellness and digital health operators for potential acquisitions to scale nationally through the VSDHOne platform [5][10] - The upcoming release of VSDHOne V2 aims to enhance automation, scalability, and modular functionality for partners nationwide [5][10] Recognition and Awards - Hydreight was recognized as one of Canada's Technology Fast 50™ award winners and ranked 77 among the fastest-growing companies in North America on the 2025 Deloitte Technology Fast 500™ [5][10]

Core Insights - Hydreight Technologies Inc. ranked No. 77 on the 2025 Deloitte Technology Fast 500™, highlighting its status as one of the fastest-growing technology companies in North America [1][2] - The company's growth is attributed to the expansion of its telehealth and pharmacy infrastructure, as well as the rapid onboarding of partners to its VSDHOne direct-to-consumer platform [2] - Hydreight previously ranked 56 on the 2024 Deloitte Technology Fast 500™ and 9 on Deloitte's 2024 Technology Fast 50™ (Canada) [2] Company Overview - Hydreight is building a large mobile clinic network in the United States, with a platform that includes over 3,000 nurses and 200 doctors across all 50 states [6][7] - The platform offers integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, enabling healthcare professionals to provide services directly to patients [7] - The company has a 503B pharmacy network and is affiliated with a certified e-script and telemedicine provider network [7] VSDHOne Platform - The VSDHOne platform simplifies entry for healthcare and wellness brands into the online space, allowing them to launch nationwide in days [8] - Compliant offerings include GLP-1s, peptides, personalized healthcare treatments, and more [8] - The platform provides a complete solution for businesses looking to enter the direct-to-consumer healthcare market, significantly reducing time and costs associated with launching services [8] Industry Context - The 2025 Technology Fast 500 companies achieved revenue growth ranging from 122% to 29,738%, with an average growth rate of 1,079% over three years [3] - The Deloitte Technology Fast 500™ has been recognizing fast-growing companies for 31 years, emphasizing the agility of private enterprises in competitive markets [4]